Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
作者信息
Menzies A M, Wilmott J S, Long G V, Scolyer R A
机构信息
Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia.
1] Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia [2] Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Missenden Road, Sydney, NSW 2050, Australia.
出版信息
Br J Cancer. 2014 Oct 14;111(8):1678-9. doi: 10.1038/bjc.2013.796. Epub 2013 Dec 24.
Abstract
摘要
相似文献
1
Intra-patient heterogeneity of BRAF mutation status: fact or fiction?患者体内BRAF突变状态的异质性：事实还是虚构？
Br J Cancer. 2014 Oct 14;111(8):1678-9. doi: 10.1038/bjc.2013.796. Epub 2013 Dec 24.
2
Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?回复：BRAF突变状态的患者内异质性：事实还是虚构？
Br J Cancer. 2014 Oct 14;111(8):1679-80. doi: 10.1038/bjc.2014.247. Epub 2014 May 15.
3
BRAF Mutation Heterogeneity in Melanoma Lesions.黑色素瘤病变中的BRAF突变异质性
Acta Derm Venereol. 2020 Jan 30;100(1):adv00045. doi: 10.2340/00015555-3394.
4
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.黑色素瘤患者的突变景观：BRAF 突变异质性的临床意义。
Br J Cancer. 2013 Nov 26;109(11):2833-41. doi: 10.1038/bjc.2013.622. Epub 2013 Nov 5.
5
Intra- and Inter-Tumor Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis.肢端黑色素瘤的瘤内和瘤间异质性：免疫组织化学分析。
Int J Mol Sci. 2019 Dec 8;20(24):6191. doi: 10.3390/ijms20246191.
6
Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?BRAF V600E突变在转移性黑色素瘤中的稳定性：治疗成功的新见解？
Br J Cancer. 2011 Jul 12;105(2):327-8. doi: 10.1038/bjc.2011.239. Epub 2011 Jun 21.
7
Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.患者体内黑色素瘤BRAFV600E突变状态的争议
Am J Dermatopathol. 2017 Apr;39(4):291-295. doi: 10.1097/DAD.0000000000000710.
8
BRAF in early stage melanoma: rationale for testing and treatment?早期黑色素瘤中的BRAF：检测与治疗的理论依据？
Br J Dermatol. 2015 Jul;173(1):9-10. doi: 10.1111/bjd.13926.
9
Melanoma BRAF fusions--letter.黑色素瘤BRAF融合——信函
Clin Cancer Res. 2014 Dec 15;20(24):6631. doi: 10.1158/1078-0432.CCR-14-0058.
10
BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.原发性皮肤黑色素瘤与相应转移灶之间BRAF突变状态的一致性：最新证据综述
Actas Dermosifiliogr. 2017 Dec;108(10):894-901. doi: 10.1016/j.ad.2016.12.025. Epub 2017 Jul 12.
引用本文的文献
1
TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.原发性和转移性黑素瘤肿瘤配对组织中 TERT、BRAF 和 NRAS 基因突变异质性。
J Invest Dermatol. 2020 Aug;140(8):1609-1618.e7. doi: 10.1016/j.jid.2020.01.027. Epub 2020 Feb 20.
2
Biology and treatment of BRAF mutant metastatic melanoma.BRAF突变转移性黑色素瘤的生物学特性与治疗
Melanoma Manag. 2016 Mar;3(1):33-45. doi: 10.2217/mmt.15.38. Epub 2016 Feb 12.
3
Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?回复：BRAF突变状态的患者内异质性：事实还是虚构？
Br J Cancer. 2014 Oct 14;111(8):1679-80. doi: 10.1038/bjc.2014.247. Epub 2014 May 15.
本文引用的文献
1
Intrapatient homogeneity of BRAFV600E expression in melanoma.黑色素瘤中 BRAFV600E 表达的患者内同质性。
Am J Surg Pathol. 2014 Mar;38(3):377-82. doi: 10.1097/PAS.0000000000000136.
2
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.转移性黑色素瘤中 RAF 抑制临床耐药的遗传特征。
Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21.
3
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.黑色素瘤患者的突变景观：BRAF 突变异质性的临床意义。
Br J Cancer. 2013 Nov 26;109(11):2833-41. doi: 10.1038/bjc.2013.622. Epub 2013 Nov 5.
4
Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?单次BRAF野生型检测足以将黑色素瘤患者排除在维莫非尼治疗之外吗？
J Invest Dermatol. 2014 May;134(5):1468-1470. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11.
5
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.通过免疫组织化学和分子检测确定转移性黑色素瘤中 BRAF 状态的原发和转移部位之间的肿瘤同质性。
PLoS One. 2013 Aug 20;8(8):e70826. doi: 10.1371/journal.pone.0070826. eCollection 2013.
6
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.免疫组织化学法高度敏感和特异，可用于检测黑色素瘤中的 V600E BRAF 突变。
Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.
7
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.原发性黑色素瘤的数量是转移性黑色素瘤患者生存的独立预测因子。
Cancer. 2012 Sep 15;118(18):4519-29. doi: 10.1002/cncr.27693. Epub 2012 Jun 26.
8
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.黑色素瘤患者原发肿瘤和转移灶中 BRAF/NRAS 突变频率。
J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21.
9
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.BRAF 突变型晚期黑色素瘤患者经 vemurafenib 治疗后出现明显、均匀、早期 [18F]氟代脱氧葡萄糖正电子发射断层扫描反应。
J Clin Oncol. 2012 May 10;30(14):1628-34. doi: 10.1200/JCO.2011.39.1938. Epub 2012 Mar 26.
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).RAF 抑制剂耐药性是由异常剪接的 BRAF(V600E)二聚化介导的。
Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.
Zotero 插件